Page 21 - Slide 1

Amgen Bone Health Mentoring Program

Monday, October 15, at 11:30am – 2:30pm ◼ Ruth Chris, Minneapolis, MN

1027: Effects of Odanacatib on BMD and Overall Safety in the

Treatment of Osteoporosis in Postmenopausal Women

Previously Treated with Alendronate

De Villiers T, Bonnick S, Odio A et al.

Session: Concurrent Oral Session 05: John H. Carsten's
Memorial Session for Osteoporosis Treatment ◼ Saturday,
October 13, 10:00 AM - 10:15 AM ◼ Room Location: Auditorium-

Main/Minneapolis Convention Center

Results Abstract Information Additional Notes
from Poster/
Conclusions ▪ Significant change in BMD with ODN therapy Presentation*
Implications at 24 months was observed in comparison to
for Canadian placebo Updated/Addition
(-0.94% and -1.35%). al Data, Key
Practice Takeaways
▪ BMD changes from baseline in ODN group:
o 1.73% for femoral neck
o 1.83% trochanter
o 0.83% for total hip
o 2.28% for lumbar spine

▪ Significant reduction in biochemical marker (u-
NTx/Cr) of bone resorption occurred in the
ODN cohort and increase in biomarkers for
bone formation (s-P1NP and s-BSAP) in
comparison to placebo.

▪ Safety and tolerability were similar across
both the treatment arms.

• ODN therapy was associated with incremental
increase in BMD among postmenopausal
women with osteoporosis following ALN
therapy. Also, ODN therapy reduced the
biomarker for bone turnover while preserving
bone formation.

Discussion Points, Key Takeaways